HK1078277A1 - Non-conjugated bile acid together with propyl gallate and/or bha to enhance the absorption of macromolecules - Google Patents

Non-conjugated bile acid together with propyl gallate and/or bha to enhance the absorption of macromolecules

Info

Publication number
HK1078277A1
HK1078277A1 HK06100995.9A HK06100995A HK1078277A1 HK 1078277 A1 HK1078277 A1 HK 1078277A1 HK 06100995 A HK06100995 A HK 06100995A HK 1078277 A1 HK1078277 A1 HK 1078277A1
Authority
HK
Hong Kong
Prior art keywords
bha
macromolecules
enhance
absorption
bile acid
Prior art date
Application number
HK06100995.9A
Other languages
English (en)
Inventor
Roger R C New
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Publication of HK1078277A1 publication Critical patent/HK1078277A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06100995.9A 2003-04-15 2006-01-20 Non-conjugated bile acid together with propyl gallate and/or bha to enhance the absorption of macromolecules HK1078277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308734.3A GB0308734D0 (en) 2003-04-15 2003-04-15 Uptake of macromolecules
PCT/GB2004/001651 WO2004091667A1 (en) 2003-04-15 2004-04-15 Uptake of macromolecules

Publications (1)

Publication Number Publication Date
HK1078277A1 true HK1078277A1 (en) 2006-03-10

Family

ID=9956848

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100995.9A HK1078277A1 (en) 2003-04-15 2006-01-20 Non-conjugated bile acid together with propyl gallate and/or bha to enhance the absorption of macromolecules

Country Status (20)

Country Link
US (1) US8314058B2 (xx)
EP (1) EP1613355B1 (xx)
JP (1) JP5047611B2 (xx)
KR (1) KR101135784B1 (xx)
CN (1) CN100506280C (xx)
AU (1) AU2004229217B2 (xx)
BR (1) BRPI0409413B8 (xx)
CA (1) CA2522146C (xx)
CY (1) CY1113461T1 (xx)
DK (1) DK1613355T3 (xx)
ES (1) ES2394640T3 (xx)
GB (1) GB0308734D0 (xx)
HK (1) HK1078277A1 (xx)
NZ (1) NZ543172A (xx)
PL (1) PL1613355T3 (xx)
PT (1) PT1613355E (xx)
RU (1) RU2349344C2 (xx)
SI (1) SI1613355T1 (xx)
WO (1) WO2004091667A1 (xx)
ZA (1) ZA200508344B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
WO2008132731A2 (en) * 2007-04-26 2008-11-06 Oramed Pharmaceuticals, Inc Methods and compositions for rectal administration of insulin
WO2010020978A1 (en) 2008-08-18 2010-02-25 Oramed Pharmaceuticals Ltd Methods and compositions for oral administration of proteins
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
EP2949331A1 (en) 2012-10-17 2015-12-02 Methylation Sciences International SRL Compositions comprising s-adenosylmethionine and a gallic acid ester
US11173124B2 (en) * 2017-10-31 2021-11-16 Medimmune Limited Oral delivery of GLP-1 peptide analogs
CN115003293A (zh) * 2020-01-23 2022-09-02 爱克赛斯(英国)有限公司 细胞摄取
WO2022157676A1 (en) * 2021-01-22 2022-07-28 Axcess (UK) Ltd Edta and egta for use in preserving the integrity of therapeutic compounds
GB2625490A (en) * 2021-01-27 2024-06-19 D&D Pharmatech Inc Pharmaceutical composition comprising large physiologically active substance and excipient
AU2022344774A1 (en) * 2021-09-07 2024-03-14 D&D Pharmatech Inc. Pharmaceutical composition comprising large physiologically active substance and excipient
KR102412437B1 (ko) 2022-03-10 2022-06-23 주식회사 보은기계 선택적 시공이 가능한 수로시스템

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB354184A (en) 1929-04-30 1931-07-29 Pharmagans Pharmaceutisches In An improved process for the production of hormone preparations
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
JPS5257313A (en) 1975-11-07 1977-05-11 Yamanouchi Pharmaceut Co Ltd Manufacture of micellar insuline emulsion preparations
JPS56138168A (en) 1980-03-31 1981-10-28 Teijin Ltd Movel active vitamin d3 derivative composition
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4789660A (en) 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IT1251685B (it) 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
JPH05246846A (ja) 1992-03-03 1993-09-24 Taiyo Kagaku Co Ltd 蛋白質の消化促進組成物
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5916566A (en) 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
AU1808897A (en) 1995-12-13 1997-07-03 Dullatur Limited A calcitonin preparation
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
AU1071200A (en) * 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
ATE234017T1 (de) 2000-03-31 2003-03-15 Council Scient Ind Res Getreidenahrungsmittel mit hohem nährwert
WO2001085256A2 (en) 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
SI1333851T1 (sl) 2000-09-18 2008-02-29 Rpg Life Sciences Ltd Sestavek, ki sam po sebi tvori emulzijo, z izboljsanimi bioabsobcijskimi in imunosupresijskimi aktivnostmi
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
CA2471081A1 (en) 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules

Also Published As

Publication number Publication date
DK1613355T3 (da) 2013-01-02
WO2004091667A1 (en) 2004-10-28
KR20060021293A (ko) 2006-03-07
JP2006523663A (ja) 2006-10-19
CA2522146C (en) 2012-06-12
PT1613355E (pt) 2012-12-26
US8314058B2 (en) 2012-11-20
EP1613355B1 (en) 2012-09-19
RU2005135428A (ru) 2006-06-10
BRPI0409413A (pt) 2006-04-25
CA2522146A1 (en) 2005-10-13
AU2004229217A1 (en) 2004-10-28
BRPI0409413B1 (pt) 2017-05-02
GB0308734D0 (en) 2003-05-21
NZ543172A (en) 2009-05-31
JP5047611B2 (ja) 2012-10-10
CN1805759A (zh) 2006-07-19
AU2004229217B2 (en) 2010-03-25
BRPI0409413B8 (pt) 2021-05-25
PL1613355T3 (pl) 2013-09-30
CY1113461T1 (el) 2016-06-22
SI1613355T1 (sl) 2013-01-31
CN100506280C (zh) 2009-07-01
ES2394640T3 (es) 2013-02-04
US20060122097A1 (en) 2006-06-08
KR101135784B1 (ko) 2012-04-16
EP1613355A1 (en) 2006-01-11
RU2349344C2 (ru) 2009-03-20
ZA200508344B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
HK1078277A1 (en) Non-conjugated bile acid together with propyl gallate and/or bha to enhance the absorption of macromolecules
IL179445A0 (en) 1-methyl-3-trifluoromethyl-pyrazole-4-carboxylic acid (ortho-phenyl)-anilides and use thereof as fungicide
IL222347A (en) 11-cis retinyl ester for use in the treatment of 11-cis and androgenic retinyl
EP1697642A4 (en) FASTENING ELEMENTS AND OTHER ARRANGEMENTS
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
IL165337A0 (en) Improvements in and relating to furniture and/or fastener mountings
GB0307352D0 (en) Improvements in and relating to the analysis of compounds
EP1725869A4 (en) MAN2AS AS MODIFICATORS OF THE IGER PATH AND USE METHOD
GB2426770B (en) Improvements in and relating to roof assemblies
EP1790351A4 (en) PERMUCOSAL COMPOSITION AND METHOD FOR IMPROVING PERMUCOSAL ABSORPTION
GB0321379D0 (en) Improvements in or relating to caravans and the like
GB2388995B (en) Improvements in and relating to alarms
GB2392699B (en) Improvements in or relating to posts
EP1757286A4 (en) USE OF 1-N-BUTYLPHTALIDE FOR THE PREVENTION OR TREATMENT OF DEMENTIA
GB2405878B (en) Improvements in and relating to weatherboarding
GB0311292D0 (en) Improvements in and relating to the movement of metal
GB2391841B (en) Caravan and construction method therefor
GB2405075B (en) Improvements in and relating to the steeping of barley
GB0413722D0 (en) Improvements in and relating to burners
AU2003256741A8 (en) Ketocampholenic acid derivatives and their use in fragrance and flavour applications
GB2391249B (en) Improvements in and relating to windows
GB0214168D0 (en) Improvements in and relating to the manufacture of welded frames for windows and doors
GB2419610B (en) Improvements in and relating to roof structures
GB0227123D0 (en) Improvements in and relating to ladders
PL352533A1 (en) Anti-recession composition and the method of its manufacture

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240414